Cargando…
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses
At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory diseases were considered to be at high risk for SARS-CoV-2 infection and the development of severe COVID-19. Data collected over the past year, however, suggest that a diagnosis of inflammatory arthritis, psoriasis...
Autores principales: | Fagni, Filippo, Simon, David, Tascilar, Koray, Schoenau, Verena, Sticherling, Michael, Neurath, Markus F, Schett, Georg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397302/ https://www.ncbi.nlm.nih.gov/pubmed/34485930 http://dx.doi.org/10.1016/S2665-9913(21)00247-2 |
Ejemplares similares
-
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
por: Schett, Georg, et al.
Publicado: (2020) -
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
por: Simon, David, et al.
Publicado: (2021) -
Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis—A case report and literature review
por: Yalcin Mutlu, Melek, et al.
Publicado: (2022) -
Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination
por: Fagni, Filippo, et al.
Publicado: (2022) -
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study
por: Simon, David, et al.
Publicado: (2022)